Read more about our exciting company and technology.

A few months ago, Flagship unveiled Sigilon Therapeutics, a Cambridge startup that is aiming to develop a new class of “living therapeutics”

Four early-stage venture-funded biotechnology companies have signed leases at 100 Binney St. in Cambridge.

Sigilon’s allogeneic cell therapy implants offer long-term but flexible dosing

Venture investors are betting that cell therapies will bring about better treatments or even cures for a widening range of diseases.

The newco will use its biocompatible Afibromer technology to develop encapsulated cell therapies for hematologic, enzyme deficiency, endocrine and metabolic disorders.

Sigilon Therapeutics launched with a $23.5 million capitalization by Flagship Pioneering today.  Sigilon will focus on fibrosis-related diseases.

“Imagine the potential of a ‘living therapeutic’ that could be implanted in the body and manufacture and release therapeutic proteins at steady levels for long periods of time,”

The latest biotech spawned from Flagship Pioneering’s in-house incubator boasts a veritable dream team of executives and board members.

Companies have been trying for years, if not decades, to find a way to encapsulate cells for therapeutic use in a way that protects them from the body’s reactions.

When encapsulated with alginate derivatives that resist the foreign-body response, human embryonic stem cell–derived beta cells restore long-term normoglycemia in immunocompetent mice without the need for immunosuppression.

Implanted spheres of a broad variety of material classes significantly abrogate foreign body reactions and fibrosis in rodent and non-human primates when the spheres are larger than 1.5 mm in diameter.

In vivo screening of a large combinatorial library of alginates identifies materials that elicit a substantially reduced foreign body response.

Host recognition and immune-mediated foreign body response to biomaterials can compromise the performance of implanted medical devices.